STOCK TITAN
  1. Home
  2. News
  3. ENVB

Enveric Biosciences Inc - ENVB STOCK NEWS

Welcome to our dedicated news page for Enveric Biosciences (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Enveric Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Enveric Biosciences's position in the market.

News
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023
Rhea-AI Summary
Enveric Biosciences (ENVB) provided a corporate update, highlighting the selection of lead candidate EB-003 for mental health disorders. The company advanced preclinical activities for EB-002, signed term sheets for out-licensing compounds, expanded its intellectual property portfolio, and reported financial results for Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
earnings
-
News
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease
Rhea-AI Summary
Enveric Biosciences (ENVB) has signed two non-binding term sheets with an undisclosed biotechnology company to potentially out-license cannabinoid-COX-2 conjugate compounds for joint disease treatment. The agreements could lead to milestone payments totaling up to $82 million, with royalty rates ranging from 0.25% to 10% on future sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.18%
Tags
none
-
News
Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets
Rhea-AI Summary
Enveric Biosciences (ENVB) secures patents for novel neuroplastogenic small-molecule therapeutics to treat depression, anxiety, and addiction disorders. The company obtains U.S. Patent No. 11,918,594 for 'Multi-Substituent Psilocybin Derivatives' and anticipates U.S. Patent No. 11,931,338 for 'Nitrilated Psilocybin Derivatives'. These patents enhance Enveric's patent portfolio, providing composition of matter claim coverage for potential drug candidates and compounds in their PsybraryTM collections. The patents also strengthen partnerships and licensing opportunities, showcasing the company's commitment to developing proprietary products for mental health disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.09%
Tags
none
News
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds
Rhea-AI Summary
Enveric Biosciences (ENVB) signs three non-binding term sheets with an undisclosed biotechnology company for out-licensing of compounds, potentially leading to $200 million in milestone payments. The agreements entail exclusive global licenses for drug development, with royalty rates up to 10% on future sales. Enveric's extensive library of novel molecules aims to address mental health conditions, showcasing the value of its proprietary drug discovery platforms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
74.49%
Tags
none
-
News
Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property
Rhea-AI Summary
Enveric Biosciences (NASDAQ: ENVB) announces the sale of a cancer-related patent portfolio to focus on developing neuroplastogenic small-molecule therapeutics for mental health disorders. The company will invest in lead candidates EB-003 and EB-002, targeting depression, anxiety, and addiction disorders. Enveric plans to continue research and development in this area while providing foundational patent protection for the undisclosed purchasers of the divested portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.29%
Tags
none
-
News
Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series
Rhea-AI Summary
Enveric Biosciences (ENVB) to initiate preclinical development of EB-003 in 2024 in preparation for IND submission
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
none
News
Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market
Rhea-AI Summary
Enveric Biosciences (ENVB) announces agreements with holders of existing warrants to exercise at a reduced price, resulting in approximately $1.8 million in gross proceeds. The new warrants will allow for the purchase of up to 2,244,000 shares of common stock at an exercise price of $1.37 per share over a term of five years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.67%
Tags
none
-
News
Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series
Rhea-AI Summary
Enveric Biosciences (ENVB) to initiate preclinical development of EB-003 in 2024 for IND submission
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.72%
Tags
none
-
News
Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373
Rhea-AI Summary
Enveric Biosciences (ENVB) Announces Positive Progress in GLP Safety and Toxicology Program for EB-373
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
clinical trial
News
Enveric Biosciences to Participate in Biotech Showcase 2024 During “J.P. Morgan Week 2024”
Rhea-AI Summary
Enveric Biosciences (ENVB) to participate in Biotech Showcase 2024, presenting business and clinical development strategy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
conferences
Stock ENVB logo
Enveric Biosciences Inc

Nasdaq:ENVB

ENVB Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

ENVB Stock Data

7.37M
7.17M
7.06%
6.71%
3.49%
Semiconductor and Related Device Manufacturing
Manufacturing
Link
US
Suwanee

About ENVB

ameri100 embodies a value system of ambition, mastery, excitement, reliability and integrity. with these values, the company is becoming an emerging global leader in sap technologies. ameri100, founded in 2013 has rapidly grown through strategic acquisitions. headquartered in princeton, new jersey, with offices in new york, georgia, kansas, pennsylvania, arizona, toronto- canada and bangalore, mumbai, chennai in india, ameri100 brings 500+ of its own best-in-class resources. the company has also evolved a unique partner ecosystem, which adds more than 4500+ resources to its delivery muscle power. ameri100 deals with sap enterprise services, digital transformation, cloud solutions, business intelligence & analytics, mobile applications and professional services. the company is also making strategic investments in artificial intelligence (ai), internet of things (iot) and robotic process automation (rpa). insight to impact!